Orion Oyj: Orion and Sun settle patent dispute

Orion Corporation (“Orion”) and Sun Pharmaceutical Industries Limited and certain other
companies belonging to Sun group of companies (together “Sun”) have executed a
settlement agreement on lawsuits filed by Orion in the United States against Sun
regarding Sun’s submissions of abbreviated new drug applications (“ANDAs”) for generic
versions of Orion’s Comtan and Stalevo products. Comtan (entacapone) is indicated as an
adjunct to levodopa/carbidopa to treat patients with idiopathic Parkinson’s disease who
experience the signs and symptoms of end-of-dose “wearing-off”. Stalevo is a combination
of carbidopa, levodopa and entacapone for the treatment of Parkinson’s disease. Both
products contain entacapone, a COMT enzyme inhibiting agent originated and patented by
Orion.

Litigations against Sun have been ongoing by Orion in the U.S. since 2007. The
settlement agreement relates to all lawsuits. Under the terms of the settlement
agreement, Sun will be able to launch generic versions of 25/100/200 mg and 37,5/150/200
mg strengths of Stalevo tablets in the US on 1 April 2012. In addition to these
strengths, Sun will be able to launch generic versions of other strengths of Stalevo
product on 2 October 2012 and generic versions of Comtan product on 1 April 2013,
unless certain conditions relating to launch are fulfilled even earlier. The parties
have agreed that Orion will supply said generic product versions to Sun. The other terms
of the settlement are confidential.

As a consequence of this settlement, Wockhardt, with which Orion executed a patent
dispute settlement on 29 April 2009, can launch other generic versions of Stalevo except
the strengths of 25/100/200 mg and 37,5/150/200mg in the US already on 1 April 2012,
and the strengths of 25/100/200 mg and 37,5/150/200 mg approximately six months after
Sun is allowed to market pursuant to license from Orion, unless certain conditions
relating to launch are fulfilled even earlier.

The settlement with Sun warrants no revision of the full-year 2010 outlook estimate for
the Orion Group provided in the stock exchange release published on 14 June 2010.

Subject to the Court’s approval, the cases will be dismissed and the challenged U.S.
Patents No. 5,446,194 and No. 6,500,867 remain in force.

In compliance with the applicable U.S. laws, Orion will file all of the agreements
related to the settlement with the United States Federal Trade Commission and the United
States Department of Justice.

Orion Corporation

Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions

Contact persons:
Timo Lappalainen, President and CEO, phone +358 10 426 3692

About Orion
Orion is a European pharmaceuticals and diagnostics company dedicated to treating and
preventing disease by discovering and developing innovative medicinal treatments and
diagnostic tests for global markets. Orion is engaged in human and veterinary drugs,
active pharmaceutical ingredients and diagnostic tests. In 2009, Orion’s net sales were
EUR 771.5 million. Operating profit was EUR 207.0 million, and the company invested EUR
95 million in pharmaceutical research and development. The number of employees is about
3,100. Orion corporate headquarters are in Espoo, Finland. Orion is listed on NASDAQ OMX
Helsinki. For more information, please visit: http://www.orion.fi/en/.

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi

HUG#1425982

Prescription drug for Parkinson’s ‘can cause porn, gambling addiction’

Sydney, June 4 (ANI): Two drug companies are being sued over allegations that prescription drugs manufactured by them for treating Parkinson’s disease are causing gambling and pornography addiction.

The group includes people who lost huge amounts of money and were facing family breakdowns as a result of compulsive gambling allegedly linked to drugs they took between 1997 and last year, reports The Sydney Morning Herald.

A few exhibited compulsive sexual behaviour such as looking at pornography on the Internet.

They are suing Pfizer Australia, over its drug Cabaser and Aspen Pharmacare, which marketed and distributed the drug Permax in Australia.

Both drugs are known as ””dopamine agonists””, and mimic the effects of dopamine in the brain, which produces a ””rush””, and believed to cause risk-taking behaviour and addictions.

The Australian class action is being run by the law firm Arnold Thomas & Becker, which says in its writ filed with the Federal Court that Pfizer Australia and Aspen Pharmacare Australia had breached a duty of care by failing to research possible side effects of their drugs, or by failing to heed research into side effects.

A directions hearing will be held today. The drug companies have not yet been served with the writ and so, have not filed a response. (ANI)

How a pet pooch can help treat Parkinson”s

London, May 13 (ANI): A significant treatment for Parkinson”s disease has been revealed by doctors – a pet pooch.

Health of a 28-year-old woman with the brain disease improved thanks to her pooch.

The woman, who started taking large doses of four different drugs a day to control symptoms three years after being diagnosed, had a morphine pump for 14 hours a day and her health was deteriorating fast.

But after being given a highland terrier by a friend, docs reported improvements in symptoms and a drop in the drugs she needed, reports The Sun.

What’s more, she no longer needed her daily morphine.

Doctors at Imperial College London, who report her case in the Journal Of Neurology, said: “Remarkably sustained benefits occurred, with improvement in her walking and symptoms including appetite, sleep and bowel function, as well as socialisation.”

Docs are not able to zero in on the reason as to how the dog had such a dramatic effect, but they say that having to walk, feed and look after the pet encouraged her to exercise regularly. (ANI)

Parkinson”s disease therapy linked to compulsive behaviours

Washington, May 11 (ANI): People who take dopamine agonist medications for Parkinson”s disease tend to display traits of compulsive behaviour— like pathological gambling, compulsive shopping, binge eating and other impulse control disorders.

These behaviours have been reported previously in patients with Parkinson”s disease, say scientists.

Preliminary estimates of impulse control disorders in this population range from 1.7 percent to 6.1 percent for gambling, 2 percent to 4 percent for compulsive sexual behavior and 0.4 percent to 3 percent for compulsive buying.

Dr. Daniel Weintraub, of the University of Pennsylvania, Philadelphia, and Philadelphia Veterans Affairs Medical Center, and colleagues studied 3,090 patients being treated for Parkinson”s disease at 46 movement disorder centers in the United States and Canada.

And they identified impulse control disorders in 13.6 percent of patients, including gambling in 5 percent, compulsive sexual behavior in 3.5 percent, compulsive buying in 5.7 percent, binge-eating disorder in 4.3 percent and two or more of those in 3.9 percent.

The disorders were more common in individuals taking dopamine agonists compared with patients not taking dopamine agonists (17.1 percent vs. 6.9 percent).

Additional variables linked with these disorders included the use of levodopa, another therapy for Parkinson”s disease; living in the United States; being younger or unmarried; smoking cigarettes; and having a family history of gambling problems.

“Dopamine agonist treatment in Parkinson”s disease is associated with 2- to 3.5-fold increased odds of having an impulse control disorder. This association represents a drug class relationship across impulse control disorders. The association of other demographic and clinical variables with impulse control disorders suggests a complex relationship that requires additional investigation to optimize prevention and treatment strategies,” wrote the authors.

Dopamine agonists are increasingly used to treat other conditions, including restless legs syndrome and fibromyalgia, noted the authors.

“Larger epidemiologic studies in these other populations are needed to examine the possible relationships between dopamine agonist treatment, other clinical features and impulse control disorders,” they concluded.

The study has been published in the May issue of Archives of Neurology, one of the JAMA/Archives journals. (ANI)

Endometrial stem cells could repair Parkinson”s related brain cell damage

Washington, May 7 (ANI): In a study on mice, researchers found that stem cells derived from the endometrium (uterine lining) could repair brain cells damaged by Parkinson”s disease, according to Yale School of Medicine researchers.

Although these are preliminary results, the findings increase the likelihood that endometrial tissue could be harvested from women with Parkinson”s disease and used to re-grow brain areas that have been damaged by the disease, according to lead author Dr. Hugh S. Taylor.

Because of their ability to divide into new cell types, stem cells could be the key to treating many different kinds of diseases, like Parkinson”s, in which the body”s own cells are damaged or depleted.

Parkinson”s is caused by a breakdown of dopamine-producing nerve cells in the brain stem. Dopamine is a neurotransmitter that stimulates the motor neurons that in turn control muscles.

When dopamine production is reduced, the nerves fail to control movement or maintain coordination.

In their study, the researchers collected and cultured endometrial tissue from nine women, and verified that they could be transformed into dopamine-producing nerve cells like those in the brain.

“The dopamine levels in the mice increased once we transferred the endometrial stem cells into their brains. This is encouraging because women have a ready supply of stem cells that are easily obtained, can differentiate into other cell types. They may have great potential for treating multiple diseases,” said Taylor.

Highlighting the benefits of using endometrial stem cells, Taylor said the ethical concerns surrounding the use of embryonic stem cells are eliminated when using adult stem cells.

Taylor also pointed out that endometrial stem cells are one of the best sources for generating neurons because they appear to be less likely to be rejected than stem cells from other sources.

“This is just the tip of the iceberg of what we will be able to do with these cells. We believe these neurons are only the first of many cell types derived from endometrium that will be used to treat a variety of diseases,” said Taylor.

The findings are published in the Journal of Cellular and Molecular Medicine. (ANI)

Voice analysis could enable early detection of Parkinson’s disease

Washington, Apr 20 (ANI): Researchers at the University of Haifa have developed a new technique that could help in the early detection of Parkinson’s disease.

Developed by Prof. Shimon Sapir, the technique involves analysis of voice and articulation.

“This is a non-invasive, reliable and accurate technique that only requires the patient to read out a few simple sentences,” explained Sapir.

Parkinson’s is diagnosed when some 60 percent of the nerve cells in the area of the brain that controls motor activity are already damaged, which compromises the effectiveness of therapy and rehabilitation.

Sapir said that the muscles controlling voice and speech are also affected by the disease in most patients, and there is some evidence suggesting that speech abnormalities may antecede the classic symptoms of the disease.

He added that theoretically, an acoustic analysis of voice is sensitive enough to help detect subtle abnormalities in speech that are present in the early stages of the disease but are not perceptible to listeners.

“Statistically speaking, the existing acoustic tests did not pick up significant differences between speech articulation of individuals with early PD and the speech of healthy individuals, even when such differences were sometimes already noticeable to the listener,” Sapir pointed out.

He suggested that “this failure to detect acoustic differences has to do with the relatively large differences between speakers’ speech signals, which is mainly due to anatomical differences between speakers”.

The method developed by Sapir minimizes the effects of speaker variability and maximizes the sensitivity of the acoustic analysis to true differences between the speech of individuals with PD and that of healthy speakers.

Sapir and his colleagues tested the utility of the acoustic analysis method.

The results showed that the analysis system was sensitive to changes that occurred in those patients who had undergone therapy for speech.

The researchers indicated that the method not only enables early diagnosis of PD but also makes it possible to track changes in PD patients that may occur in response to treatment or as the disease progresses.

The results have been published in the Journal of Speech, Language, and Hearing Research. (ANI)

Soccer nanoballs may harbour Alzheimer”s, cancer cure

Washington, April 1 (ANI): Soccer-ball-shaped carbon nanoparticles may harbour the cure for Parkinson””s disease, Alzheimer””s and even cancer, according to a new American research.

The study, conducted by a Los Alamos National Laboratory toxicologist and a multidisciplinary team of researchers, has been published in Toxicology and Applied Pharmacology.

The research represents the first-ever observation of this kind for spherical fullerenes – cage-like molecules composed of 60 carbon atoms.

Fullerenes, also known as buckyballs, take their names from the late Buckminster Fuller because they resemble the geodesic dome concept that he popularised.

Each buckyball is a skeletal cage of carbon about the size of a virus. They show potential for creating stronger, lighter structures or acting as tiny delivery mechanisms for designer drugs or antibiotics, among other uses. About four to five tons of carbon nanoparticles are manufactured annually.

Los Alamos toxicologist Rashi Iyer, the principal research lead and coauthor of the paper, said: “Nanomaterials are the 21st century revolution.

“We are going to have to live with them and deal with them, and the question becomes, ””How are we going to maximize our use of these materials and minimize their impact on us and the environment?”””

Iyer and lead author Jun Gao, also a Los Alamos toxicologist, exposed cultured human skin cells to several distinct types of buckyballs.

The differences in the buckyballs lay in the spatial arrangement of short branches of molecules coming off of the main buckyball structure.

One buckyball variation, called the “tris” configuration, had three molecular branches off the main structure on one hemisphere; another variation, called the “hexa” configuration, had six branches off the main structure in a roughly symmetrical arrangement; the last type was a plain buckyball.

The scientists discovered that cells exposed to the tris configuration underwent premature senescence – what might be described as a state of suspended animation. In other words, the cells did not die as cells normally should, nor did they divide or grow.

This arrest of the natural cellular life cycle after exposure to the tris-configured buckyballs may compromise normal organ development, leading to disease within a living organism. Briefly, the tris buckyballs were toxic to human skin cells.

Furthermore, the cells exposed to the tris arrangement caused unique molecular level responses suggesting that tris-fullerenes may potentially interfere with normal immune responses induced by viruses.

The team is now pursuing research to determine if cells exposed to this form of fullerenes may be more susceptible to viral infections.

Ironically, the discovery could also lead to a novel treatment strategy for combating several debilitating diseases.

In diseases like Parkinson””s or Alzheimer””s, nerve cells die or degenerate to a nonfunctional state. A mechanism to induce senescence in specific nerve cells could delay or eliminate onset of the diseases.

Similarly, a disease like cancer, which spreads and thrives through unregulated replication of cancer cells, might be fought through induced senescence. This strategy could stop the cells from dividing and provide doctors with more time to kill the abnormal cells.

Because of the minute size of nanomaterials, the primary hazard associated with them has been potential inhalation – similar to the concern over asbestos exposure.

Iyer said: “Already, from a toxicological point of view, this research is useful because it shows that if you have the choice to use a tris- or a hexa-arrangement for an application involving buckyballs, the hexa-arrangement is probably the better choice.”

She added: “These studies may provide guidance for new nanomaterial design and development.” (ANI)

For depressed physically ill patients, antidepressants can prove beneficial

Washington, Mar 17 (ANI): Antidepressants are effective at treating depression in patients suffering from physical illnesses, according to a new study.

The systematic review was done by Cochrane researchers at King”s Health Partners Academic Health Sciences Centre in the UK.

The review included 51 studies comparing antidepressants to placebos. Most studies trialled selective serotonin reuptake inhibitors or tricyclic antidepressants. A total of 3603 patients were involved, suffering from physical illnesses including stroke, HIV/AIDS, Parkinson”s disease and cancer. The researchers found that antidepressants were more effective than placebos, although patients receiving antidepressants were more likely to experience adverse effects, including sexual dysfunction and dry mouth.

For every six people receiving treatment, one more could be expected to benefit at between six and eight weeks if they were taking antidepressants.

Lead author Lauren Rayner of King”s College London said, “Although trials were small, they do seem to indicate a genuine benefit associated with antidepressants. However, patients with more severe physical illness and more severely depressed patients were not included in the trials. It is possible that those with more severe illness don”t respond so well to treatment with antidepressants. This is something that should be addressed in further studies.”

Senior investigator Professor Matthew Hotopf, Institute of Psychiatry, King”s College London added: “As a clinician I see many patients struggling with the effects of physical disease on their mental health. Doctors should take into account patients” preferences, symptoms and possible interactions with any other medications they are taking when prescribing antidepressants to physically ill patients”.

He concludes: “This is a critical area of research which will help doctors maximise a patient”s treatment and recovery from the mental and physical symptoms of illness.” (ANI)

Michael J Fox to be honoured for Parkinson”s disease research

London, Mar 8 (ANI): Actor Michael J Fox is set to receive an honorary degree of medicine from Sweden”s Karolinska Institute, for his efforts in raising funds and awareness for Parkinson”s Disease.

The ‘Back To The Future’ star will be felicitated in a ceremony in New York.

Fox started the Michael J Fox Foundation for Parkinson”s Research, after he was diagnosed with Parkinson”s in 1991.

The foundation has contributed more than 175m dollars to research for developing drugs to fight Parkinson”s, since 2000, reports the BBC.

Karolinska Institute also awards the annual Nobel Prize in medicine. (ANI)

Single gene behind essential tremor, Parkinson’s disease identified

Washington, September 2 (ANI): A single gene promotes development of essential tremor in some patients and Parkinson’s disease in others has been identified by an international team of researchers.

In a study report published in Parkinsonism and Related Disorders, Mayo Clinic researchers in Florida and their collaborators worldwide note that patients with essential tremor shake when they move, while those with Parkinson’s disease shake when they are at rest.

They further state that a variant in LINGO1, a gene involved in neuronal survival, is the first proven evidence of a common genetic component in the development of both disorders.

Analysing their findings, the researchers have come to the conclusion that mutations in this gene are potentially responsible for five percent of patients with Parkinson’s disease, and five percent of patients with essential tremor.

Lead researcher Dr. Carles Vilarino-Guell, of Mayo Clinic, said: “There is a mutation in the gene that must be causing or contributing to Parkinson’s disease in some people and essential tremor in others.”

He, however, added that that did not mean that people with essential tremor have an increased risk of developing Parkinson’s disease.

The findings are intriguing because “although essential tremor and Parkinson’s disease are considered to be different diseases, researchers have been arguing for a long time about whether essential tremor is a milder, preliminary form of Parkinson’s disease, and they have been looking for the genetic connection between these disorders,” he said.

“Now we know LINGO1 is the first gene identified,” he added.

The scientists have yet to identify any specific mutation or mutations on LINGO1 responsible for either disorder.

“The easiest explanation is that there are two separate and clearly distinct mutations in the gene contributing to the disorders. But because this gene doubles the risk of developing either disease and it is found at the same frequency in both diseases, it is possibly the same mutation,” Dr. Vilarino-Guell said.

“Both diseases are also affected by environmental factors, and that may influence which disorder a person would be more likely to develop,” he added. (ANI)

Novel therapeutic target for Parkinson’s disease identified

Washington, Aug 29 (ANI): Scientists from University of Helsinki Institute of Biotechnology have identified a novel therapeutic target for Parkinson’s disease.

Lead researcher Professor Raimo K. Tuominen and colleagues have identified a growth factor that can be used to halt the progress of damage brought on by a nerve poison, and possibly restore the function of damaged cells.

The team is investigating two new nerve growth factors. MANF (mesencephalic astrocyte-derived neurotrophic factor) and CDNF.

MANF is released from glial cells in the midbrain and is a member of the same growth factor family as CDNF.

The team found that in the experimental PD model, MANF and CDNF injections into the brain prevented dopamine nerve destruction caused by nerve poison and to some extent even restored the function of damaged cells in rats.

This suggests that MANF spreads more readily in brain tissue than other known growth factors.

This may be a highly significant finding in respect to the development of growth factor therapy for PD. (ANI)

Ali visit to Hatton’s health center took him by surprise

London, Aug.27 (ANI): Boxing legend Ricky Hatton admitted his “jaw hit the floor” when he met his all-time hero Muhammad Ali.

Ali, who is fighting Parkinson’s disease, visited Hatton’s health centre in Manchester at the start of a UK tour.

The three-time heavyweight champion of the world, 67, was expected to arrive in a wheelchair, but instead told his aides he wanted to walk into the gym.

The Daily Star quoted the 30-year-old as saying: “A few years ago if you’d said Muhammad Ali would be coming to my local town, Hyde, I’d have said: ‘No way’. You knew it wouldn’t happen. The fact he has put himself out to come to my gym brings a tear to the eye.” (ANI)

Can sunscreen nanoparticles cause Alzheimer’s disease?

London, Aug 25 (ANI): Researchers at University of Ulster are all set to probe whether some man-made nanoparticles, such as those found in sunscreens, are linked with Alzheimer’s disease.

Led by professor Vyvyan Howard and Dr Christian Holscher at the Biomedical Sciences Institute in Coleraine, the research will look into whether engineered nanoparticles can induce neurodegenerative disease.

Howard said that they would examine whether there was a significant risk associated with such nanoparticles.

“The overall science and technology objective of this programme is to determine if engineered nanoparticles could constitute a significant neuro-toxicological risk to humans for two diseases – Alzheimer’s and Parkinson’s,” the BBC quoted him as saying.

The experts will be looking at nanoparticles present in chemicals found in sunscreens and an additive in some diesel fuels – titanium dioxide and cerium oxide – and their connection to Alzheimer’s and Parkinson’s diseases.

“There is now firm evidence that some engineered nanoparticles entering intravenously or via lungs can reach the brains of small animals. Indeed they lodge in almost all parts of the brain and there are no efficient clearance mechanisms to remove them once there,” said Howard.

“There are also suggestions that nanoscale particles arising from urban pollution have reached the brains of animals and children living in Mexico City.

“It has recently been discovered that nanoparticles can have highly significant impacts on the rate of misfolding of key proteins associated with neurodegenerative diseases like Alzheimer’s and Parkinson’s disease.

“The brain itself is a very special organ. It cannot repair by replacing nerve cells, the ones you get at birth have to last all your life, which makes them peculiarly vulnerable to long term low dose toxicity,” he added.

Dr. Susanne Sorensen, head of research at the Alzheimer’s Society, said: “We do not advise people to stop using sunscreen as it has been proven to reduce your risk of developing skin cancer however we welcome research into the long term safety of modern products.

“There is currently no research data directly linking the use of sun screen to development of Alzheimer’s disease,” she added. (ANI)

Study finds link between pesticide levels in blood and Parkinson’s disease

Washington, July 14 (ANI): In a new study, researchers at UT Southwestern Medical Center have found that people with Parkinson’s disease have significantly higher blood levels of a particular pesticide than healthy people or those with Alzheimer’s disease.

The researchers found the pesticide beta-HCH (hexachlorocyclohexane) in 76 percent of people with Parkinson’s, compared with 40 percent of healthy controls and 30 percent of those with Alzheimer’s.

According to researchers, the finding may provide the basis for a beta-HCH blood test to identify individuals at risk for developing Parkinson’s disease.

The results also point the way to more research on environmental causes of Parkinson’s.There’s been a link between pesticide use and Parkinson’s disease for a long time, but never a specific pesticide. This is particularly important because the disease is not diagnosed until after significant nerve damage has occurred. A test for this risk factor might allow for early detection and protective treatment,” said Dr. Dwight German, professor of psychiatry at UT Southwestern and a senior author of the paper.

The study involved 113 participants, ages 50 to 89. Fifty had Parkinson’s, 43 were healthy and 20 had Alzheimer’s. The researchers tested the subjects’ blood for 15 pesticides known as organochlorines.

These pesticides, which include the well-known DDT, were widely used in the U.S. from the 1950s to the 1970s but are more tightly regulated now. They persist in the environment for years without breaking down.

In the body, they dissolve in fats and are known to attack the type of brain nerves that die in Parkinson’s disease, the researchers said.

The study appears in the July issue of Archives of Neurology. (ANI)

Artificial nerve cells come closer to reality

London, July 8 (ANI): Taking a step closer towards the creation of artificial nerve cells, scientists have now found that neurotransmitters can be used to communicate between the nerve cells in the body.

Just like cochlear implants and electrodes, current methods to stimulate nerve signals in the nervous system are based on electrical stimulation.

Cochlear implants are surgically inserted into the cochlea in the inner ear, while electrodes are used directly in the brain.

One problem with this method is that all cell types in the vicinity of the electrode are activated, which gives undesired effects.

But scientists have now used an electrically conducting plastic to create a new type of “delivery electrode” that instead releases the neurotransmitters that brain cells use to communicate naturally.

The technique is beneficial because only neighbouring cells that have receptors for the specific neurotransmitter, and that are thus sensitive to this substance, will be activated.

The scientists have shown that the delivery electrode can be used to control the hearing function in the brains of guinea pigs.

“The ability to deliver exact doses of neurotransmitters opens completely new possibilities for correcting the signalling systems that are faulty in a number of neurological disease conditions,” Nature magazine quoted professor Agneta Richter-Dahlfors, who has led the work, as saying.

Scientists want to continue with the development of a small unit that can be implanted into the body.

The unit could be programmed such that the release of neurotransmitters takes place as often as, or as seldom as, required in order to treat the individual patient.

Research projects that are already under way are targeted towards hearing, epilepsy and Parkinson’s disease.

The technology has been published in an article in Nature Materials. (ANI)

Exposure to nitrates linked to Alzheimer’s, Parkinson’s deaths

Washington, July 6 (ANI): Exposure to nitrates through environment and food can increase death risk from diseases like Alzheimer’s, diabetes mellitus, and Parkinson’s, say researchers.

Led by Dr. Suzanne de la Monte of Rhode Island Hospital, the study has found strong parallels between age adjusted increases in death rate from Alzheimer’s, Parkinson’s, and diabetes and the progressive increases in human exposure to nitrates, nitrites and nitrosamines through processed and preserved foods as well as fertilizers.

The authors believe that increase in exposure plays a critical role in the cause, development and effects of the pandemic of these insulin-resistant diseases.

“We have become a ‘nitrosamine generation.’ In essence, we have moved to a diet that is rich in amines and nitrates, which lead to increased nitrosamine production,’ said de la Monte.

“We receive increased exposure through the abundant use of nitrate-containing fertilizers for agriculture,” she added.

The investigators suggest that the cellular alterations that occur as a result of nitrosamine exposure are fundamentally similar to those that occur with aging, as well as Alzheimer’s, Parkinson’s and Type 2 diabetes mellitus.

The researchers recognize that an increase in death rates is anticipated in higher age groups.

Yet when the researchers compared mortality from Parkinson’s and Alzheimer’s disease among 75 to 84 year olds from 1968 to 2005, the death rates increased much more dramatically than for cerebrovascular and cardiovascular disease, which are also aging-associated.

In Alzheimer’s patients, the death rate increased 150-fold, from 0 deaths to more than 150 deaths per 100,000.

Parkinson’s disease death rates also increased across all age groups.

The authors state that the time course of the increased prevalence rates of Alzheimer’s, Parkinson’s and diabetes cannot be explained on the basis of gene mutations.

They instead mirror the classical trends of exposure-related disease. Because nitrosamines produce biochemical changes within cells and tissues, it is conceivable that chronic exposure to low levels of nitrites and nitrosamines through processed foods, water and fertilizers is responsible for the current epidemics of these diseases and the increasing mortality rates associated with them.

The study has been published in the Journal of Alzheimer’s Disease. (ANI)

Light therapy may help treat Parkinson’s disease

Washington, June 23 (ANI): A new study from the University of Virginia Health System has shown that low level light therapy (LLLT) could help treat patients with Parkinson’s disease.

The in vitro study, led by Patricia A. Trimmer, PhD, associate professor of neurological research at the UVA School of Medicine, showed that a single, brief treatment with a 810 nm low level, near-infrared laser increased for two-hours the velocity of mitochondrial movement in cells taken from patients with sporadic Parkinson’s disease, speeding it up to levels comparable to cells from a disease-free, age-matched control group.

“Our findings provide early-stage confirmation that LLLT has the potential to improve neuronal function in many patients with PD and other neurological diseases,” says Trimmer.

The researchers found that the most dysfunctional patient cells had the weakest response to LLLT. The therapy had no impact on healthy control group cells.

Mitochondria are the cellular engines that transform food into fuel in our bodies and perform their work in the energy-intensive tissue of our brains, retinas, hearts and skeletal muscles.

In patients with Parkinson’s disease, mitochondria become metabolically and functionally compromised.

Cells slow down, become ineffective in generating energy and over-produce oxygen free radicals.

If produced in excess, oxygen free radicals chemically attack all cell components, including proteins, DNA and lipids in cell membranes.

Trimmer pointed out that numerous investigational Parkinson’s disease drugs have demonstrated efficacy in animal models but proven largely ineffective in humans.

However, LLLT is already being used to treat a wide range of human conditions involving injury and inflammation. It has also been evaluated in Phase 2 clinical trials as a way to ameliorate the consequences of stroke.

The study has been published online by Molecular Neurodegeneration on June 17, 2009. (ANI)

Pesticide exposure raises Parkinson’s risk

Washington, Apr 22 (ANI): Exposure to pesticides can increase the risk of Parkinson’s disease, say researchers.

Researchers from University of California, Los Angeles have found that fungicide maneb and herbicide paraquat can have detrimental effects on humans.

In a new epidemiological study of Central Valley residents who have been diagnosed with Parkinson’s disease, researchers found that years of exposure to the combination of these two pesticides increased the risk of Parkinson’s by 75 percent.
urther, for people 60 years old or younger diagnosed with Parkinson’s, earlier exposure had increased their risk for the disease by as much as four- to six-fold.

Reporting in the April 15 issue of the American Journal of Epidemiology, Beate Ritz, professor of epidemiology at the UCLA School of Public Health, and Sadie Costello, a former doctoral student at UCLA who is now at the University of California, Berkeley, found that Central Valley residents who lived within 500 meters of fields sprayed between 1974 and 1999 had a 75-percent increased risk for Parkinson’s.

In addition, people who were diagnosed with Parkinson’s at age 60 or younger were found to have been at much higher risk because they had been exposed to maneb, paraquat or both in combination between 1974 and 1989, years when they would have been children, teens or young adults.

The researchers enrolled 368 longtime residents diagnosed with Parkinson’s and 341 others as a control group.

Parkinson’s disease is a degenerative disorder of the central nervous system that often impairs motor skills, speech and other functions. It has been reported to occur at high rates among farmers and in rural populations, contributing to the hypothesis that agricultural pesticides may be partially responsible.

“Because pesticides applied from the air or ground may drift from their intended treatment sites – with measurable concentrations subsequently detected in the air, in plants and in animals up to several hundred meters from application sites – accurate methods of estimating environmental exposures in rural communities have long been sorely needed,” said Ritz, the study’s senior author and vice chair of the School of Public Health’s epidemiology department.

So Ritz, Costello and colleague Myles Cockburn from the University of Southern California, developed a geographic information system-based tool that estimated human exposure to pesticides applied to agricultural crops. This GIS tool combined land-use maps and pesticide-use reporting data from the state of California. Each pesticide-use record includes the name of the pesticide’s active ingredient, the amount applied, the crop, the acreage of the field, the application method and the date of application.

Research subjects were recruited between 1998 to 2007; telephone interviews were conducted to obtain their demographic and exposure information.

Detailed residential history forms were mailed to subjects in advance of their interviews and were reviewed in person or over the phone. The researchers recorded and added lifetime residential histories and estimated ambient exposures into the system for all historical addresses at which participants had resided between 1974 and 1999, the period covered by the pesticide-use data.

“The results confirmed two previous observations from animal studies. One, that exposure to multiple chemicals may increase the effect of each chemical. That’s important, since humans are often exposed to more than one pesticide in the environment. And second, that the timing of exposure is also important,” Ritz said. (ANI)

Fish oil could help prevent Parkinson’s disease

Washington, Apr 20 (ANI): Incorporating an omega three fatty acid- found in fish oil- in the diet could help prevent diseases like Parkinson’s and Huntington’s.

Dr. Nicolas Bazan, form the Louisiana State University Health Sciences Center, showed that the omega three fatty acid, docosahexaenoic acid (DHA), prevented the misfolding of a protein resulting from a gene mutation in neurodegenerative diseases.

For the study, researchers developed a cell model with a mutation of the Ataxin-1 gene.

The defective Ataxin-1 gene induces the misfolding of the protein produced by the gene, which fails to get properly processed by the cell machinery and thus results in tangled clumps of toxic protein that eventually kill the cell.

The Ataxin-1 misfolding defect could cause Spinocerebellar Ataxia- a disabling disorder that affects speech, eye movement, and hand coordination at early ages of life.

Researchers found that DHA could protect cells from this defect.

Previously, researchers had discovered that neuroprotectin D1 (NPD1)-a naturally occurring molecule in the human brain that is derived from DHA-also promotes brain cell survival.

In this system NPD1 could set free the dying cells with the pathological type of Ataxin-1, keeping their integrity intact.

“These experiments provide proof of principle that neuroprotectin D1 can be applied therapeutically to combat various neurodegenerative diseases,” said Bazan.

He added: “Furthermore, this study provides the basis of new therapeutic approaches to manipulate retinal pigment epithelial cells to be used as a source of NPD1 to treat patients with disorders characterized by this mutation like Parkinson’s, Retinitis Pigmentosa and some forms of Alzheimer’s Disease.”

The study was presented at the Ernest N. Morial Convention Center, Nouvelle C Room, at the American Society for Nutrition, Experimental Biology 2009 Annual Meeting. (ANI)

Parkinson’s disease medication may trigger compulsive gambling, hypersexuality

Washington, April 9 (ANI): Mayo Clinic researchers have found that medications recommended to patients suffering from Parkinson’s disease may trigger destructive behaviours, such as compulsive gambling or hypersexuality.

The researchers have revealed that their study extends findings from two Mayo case series published in 2005, which reported a connection between dopamine agonist medications and compulsive gambling or hypersexuality.

Dopamine agonists are a class of drugs that are commonly used to treat Parkinson’s disease, and some times restless legs syndrome.

The researchers point out that these drugs uniquely stimulate brain limbic circuits, which are thought to be fundamental substrates for emotional, reward and hedonistic behaviours.

“The 2005 case series alerted us that something bad was happening to some unfortunate people. This study was done to assess the likelihood that this effect would happen to the average Parkinson’s patient treated with these agents,” says Dr. J. Michael Bostwick, Mayo Clinic psychiatrist who spearheaded the new study.

During the study, the research team analysed the medical records of patients with Parkinson’s disease residing in counties surrounding Rochester, Minnesota, who received their primary neurological care at Mayo Clinic in Rochester between 2004 and 2006.

The group included 267 patients, 66 of whom were taking dopamine agonists for their Parkinson’s disease.

And, of those 66, 38 were taking the drugs in therapeutic doses, that is doses expected to be at least minimally beneficial.

The researchers observed that seven patients experiencing new-onset compulsive gambling or hypersexuality were taking dopamine agonists in therapeutic doses.

They said that none of the other Parkinson’s disease patients developed compulsive gambling habits or hypersexuality, including the 28 patients on subtherapeutic dopamine agonist doses or the other 201 patients not taking dopamine agonists.

None of the 178 patients treated only with the standard drug for Parkinson’s disease, carbidopa/levodopa, developed such behaviours.

“It is crucial for clinicians prescribing dopamine agonists to apprise patients as well as their spouses or partners about this potential side effect. The onset can be insidious and overlooked until life-altering problems develop,” says Dr. J. Eric Ahlskog, Mayo Clinic neurologist who co-authored and treated many of the patients in the 2005 study.

“It also is worth noting that the affected patients were all taking therapeutic doses. Very low doses, such as those used to treat restless legs syndrome, carry much less risk.

“For some patients, a reduction in the dose of the dopamine agonist may prove to be sufficient treatment, although total elimination of the offending drug is often necessary,” adds Dr. Ahlskog

A research article on the latest findings has been published in Mayo Clinic Proceedings. (ANI)